Overview

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Status:
Not yet recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of mild or moderate methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.

Phase:

Phase 1

Details

Lead Sponsor:

University of Wisconsin, Madison

Collaborator:

Revive Therapeutics, Ltd.

Treatments:

Psilocybin